Loading stock data…
NSPR
$1.15-0.03 (-2.54%)
Market ClosedLast close May 1
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InspireMD, Inc. in the Healthcare sector is trading at $1.15. The stock is currently near its 52-week low of $1.12, remaining 41.9% below its 200-day moving average. Technical signals show oversold RSI of 14 and bearish MACD signal, explaining why NSPR maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 14) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.15
Potential Upside
5%
Whystock Fair Value$1.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationall...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.89%
Volume
Today's trading volume
41,300
Recent News
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
InspireMD Inc (NSPR) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Advancements
InspireMD Inc (NSPR) reports a 62% revenue increase, driven by Seaguard Prime's US launch and international growth, despite facing operational challenges.
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of +36.36% and +14.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +41.48% and +2.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...